MedTrace Logo

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-08-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the change in brachial artery reactivity in HIV-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen

Conditions

Interventions

DRUG

Atazanavir

atazanavir 400 mg once daily

DRUG

current antiretroviral regimen

Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus \> 2 NRTIs

Sponsors & Collaborators

Principal Investigators

  • Robert L Murphy, MD · Northwestern University

  • James H Stein, MD · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States
  • Argentina
  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225017 on ClinicalTrials.gov